Biogen's Early-Stage Alzheimer's Data Continues to Impress Post author:Sam Post published:November 1, 2017 Post category:BioPharma ALZ’s researchers continue to see hope in Biogen’s aducanumab. Source: BioSpace You Might Also Like Star R&D Duo Nabs $65 Million for Iterum to Develop Shelved Pfizer Antibiotic May 18, 2017 Roche Launches The Cobas EGFR Mutation Test V2 For Use With Either Plasma Or Tumor Tissue Samples March 13, 2017 The Elephant in the Room—Investors Pushing for Lower Pay for 1st Female GlaxoSmithKline CEO March 5, 2017
Roche Launches The Cobas EGFR Mutation Test V2 For Use With Either Plasma Or Tumor Tissue Samples March 13, 2017
The Elephant in the Room—Investors Pushing for Lower Pay for 1st Female GlaxoSmithKline CEO March 5, 2017
